RadSep’s Purification and Molecular Recognition Technology
February 19, 2026
RadSep, Inc., a subsidiary of IBC Advanced Technologies, Inc., provides state-of-the-art purification technology and novel chelators for medical radioisotopes and their precursors (Ac-225, Ra-224, Ra-225, Ra-226, Ra-228, Th-228, Th-232, Pb-212, Cu-67, and more).
RadSep offers Molecular Recognition Technology™ (MRT™) resins that are extremely selective, stable and simple to use. First-pass recoveries and purities of 99.9+% are achieved due to the high selectivity and capacity of MRT™ resins. In addition, their high radiolytic stability enables reuse for multiple separation cycles. MRT™ separation systems deliver maximum useable activity while minimizing manufacturing space and waste. Thus, MRT™ makes radioisotope production compatible with radiopharmaceutical manufacturing at scale.
As an award-winning manufacturer, RadSep also offers highly selective chelators for various radioisotopes.
Learn more at https://radsep.com
Recent News
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America’s Healthcare Resilience
